News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,720 Results
Type
Article (39998)
Company Profile (249)
Press Release (664472)
Multimedia
Podcasts (58)
Webinars (14)
Section
Business (204273)
Career Advice (2011)
Deals (35454)
Drug Delivery (95)
Drug Development (81131)
Employer Resources (172)
FDA (16245)
Job Trends (14886)
News (345487)
Policy (32604)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1437)
Antibody-drug conjugate (ADC) (152)
Approvals (16243)
Artificial intelligence (307)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (120)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (363)
Cancer (2848)
Cardiovascular disease (209)
Career advice (1681)
Career pathing (30)
CAR-T (183)
CDC (30)
Cell therapy (494)
Cervical cancer (22)
Clinical research (66825)
Collaboration (1011)
Company closure (3)
Compensation (680)
Complete response letters (21)
COVID-19 (2624)
CRISPR (56)
C-suite (321)
Cystic fibrosis (111)
Data (2972)
Decentralized trials (2)
Denatured (20)
Depression (58)
Diabetes (346)
Diagnostics (6421)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (135)
Drug pricing (120)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87436)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113717)
Executive appointments (845)
FDA (17884)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (925)
Gene editing (129)
Generative AI (22)
Gene therapy (371)
GLP-1 (777)
Government (4499)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2795)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3636)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (491)
Leadership (18)
Legal (7929)
Liver cancer (79)
Lung cancer (399)
Lymphoma (207)
Machine learning (11)
Management (58)
Manufacturing (380)
MASH (90)
Medical device (13456)
Medtech (13461)
Mergers & acquisitions (19575)
Metabolic disorders (844)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (31)
Neuroscience (2107)
NextGen: Class of 2025 (6516)
Non-profit (4488)
Now hiring (47)
Obesity (424)
Opinion (217)
Ovarian cancer (101)
Pain (104)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (295)
Patient recruitment (160)
Peanut (50)
People (57675)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20826)
Phase II (29437)
Phase III (21902)
Pipeline (1618)
Policy (197)
Postmarket research (2563)
Preclinical (8864)
Press Release (64)
Prostate cancer (139)
Psychedelics (35)
Radiopharmaceuticals (253)
Rare diseases (454)
Real estate (5918)
Recruiting (66)
Regulatory (22615)
Reports (50)
Research institute (2324)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (155)
Series B (106)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (75)
Tariffs (57)
The Weekly (36)
Vaccines (777)
Venture capital (53)
Weight loss (254)
Women's health (45)
Worklife (16)
Date
Last 7 days (365)
Last 30 days (1764)
Last 365 days (31173)
2025 (16612)
2024 (35220)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32110)
2016 (31483)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38201)
Australia (6231)
California (7400)
Canada (2349)
China (668)
Colorado (320)
Connecticut (316)
Delaware (192)
Europe (82085)
Florida (1114)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (360)
Iowa (16)
Japan (226)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1019)
Massachusetts (5501)
Michigan (245)
Minnesota (448)
Mississippi (3)
Missouri (89)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2066)
New Mexico (28)
New York (2081)
North Carolina (1076)
North Dakota (8)
Northern California (3258)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1608)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2763)
Tennessee (125)
Texas (1114)
United States (27446)
Utah (219)
Virginia (182)
Washington D.C. (72)
Washington State (629)
West Virginia (4)
Wisconsin (65)
704,720 Results for "ambrx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
June 30, 2025
·
5 min read
Deals
Johnson & Johnson Completes Acquisition of Ambrx
Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc.
March 7, 2024
·
5 min read
Deals
Ambrx Announces Sale to Johnson & Johnson
Ambrx Biopharma, Inc., or Ambrx, announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx’s closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion.
January 8, 2024
·
9 min read
Biotech Beach
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
Ambrx Biopharma, Inc., announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.
March 6, 2024
·
4 min read
Biotech Beach
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Ambrx Biopharma, Inc., or Ambrx, announced that the Company will be added to the NASDAQ Biotechnology Index, effective prior to the market open on Monday, December 18, 2023.
December 14, 2023
·
3 min read
Biotech Beach
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will participate in a fireside chat and one-on-one meetings at the Cantor Fitzgerald Global Healthcare conference, being held in New York, NY.
September 18, 2023
·
3 min read
Deals
J&J to Purchase Antibody-Drug Conjugate Company Ambrx for $2 Billion
The pharmaceutical giant will pay $28 a share to acquire Ambrx’s pipeline of ADCs, particularly its lead candidate for prostate cancer.
January 8, 2024
·
2 min read
·
Connor Lynch
Deals
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired.
January 8, 2024
·
9 min read
Biotech Beach
FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ambrx’s proprietary anti-PSMA antibody-drug conjugate (ADC) investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.
July 19, 2023
·
5 min read
Biotech Beach
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
Ambrx Biopharma Inc., Ambrx, announced that it will host an in-person key opinion leader event during the European Society for Medical Oncology Congress 2023.
September 26, 2023
·
7 min read
1 of 70,472
Next